In this study, we demonstrate PD-L1 expression by tumor cells in 47.6% of patients with BPDCN, suggesting a possible role for therapeutic inhibition of the PD1/PD-L1 axis in patients with this disease. The gene discussed is CD274; the disease is neoplasm.